Elranatamab (ELRA), a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody, has demonstrated efficacy and manageable safety in patients with relapsed or refractory multiple myeloma (RRMM). The MagnetisMM-32 study, a phase 3, open-label, multicenter, randomized trial, aims to compare ELRA monotherapy with standard treatments including elotuzumab-pomalidomide-dexamethasone (EPd), pomalidomide-bortezomib-dexamethasone (PVd), or carfilzomib-dexamethasone (Kd) in approximately 492 patients with RRMM. Patients will be randomized 1:1 and stratified by prior therapy lines and disease stage. The primary endpoint is progression-free survival (PFS) by blinded independent central review (BICR), with overall survival (OS) as a key secondary endpoint. 

Key Points:

• Elranatamab (ELRA), a BCMA-CD3 bispecific antibody, is being evaluated in MagnetisMM-32, a phase 3 trial in RRMM.
• Study compares ELRA monotherapy vs EPd, PVd, or Kd in 492 patients, randomized 1:1.
• Primary endpoint: PFS by BICR; secondary endpoint: OS.
• Inclusion criteria: RRMM, measurable disease, prior specific therapies; exclusion criteria: recent stem cell transplant, active infections, prior BCMA- or CD3-targeted therapies.
• Study will assess safety, pharmacokinetics, immunogenicity, and quality of life outcomes.

Authors:

Steven Robert Schuster, Satoshi Ito, Margaret Hoyle, Anne Yver, Fangxin Hong, and Gregory Finn

Clinical trial information: NCT06152575